Phase III data on E 7080 in Thyroid Cancer published in NEJM-Eisai
Results from the pivotal Phase III SELECT Study of E7080 (lenvatinib), from Eisai, in Differentiated Cancer of the thyroid cancer (RAI-refractory DTC) were published online in the New England Journal of Medicine (NEJM). Lenvatinib is under review with the FDA and is not currently approved for use in the United States. The trial (Study 303) met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival. Secondary endpoints of the study included overall response rate, overall survival, and safety.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.